<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002910</url>
  </required_header>
  <id_info>
    <org_study_id>J-DEFINE</org_study_id>
    <nct_id>NCT02002910</nct_id>
  </id_info>
  <brief_title>Japan Study of Distal Evaluation of Functional Significance of Intra-arterial Stenosis Narrowing Effect</brief_title>
  <official_title>Japan Study of Distal Evaluation of Functional Significance of Intra-arterial Stenosis Narrowing Effect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associations for Establishment of Evidence in Interventions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Associations for Establishment of Evidence in Interventions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether instantaneous wave-Free Ratio(iFR)/Fractional Flow Reserve(FFR) guided&#xD;
      treatment strategy makes the postulated treatment strategy by Coronary Angiogram(CAG) guide&#xD;
      change and to analyze the cost-effectiveness of its dual diagnosis.&#xD;
&#xD;
      To investigate difference between SYNTAX score evaluated CAG and functional SYNTAX score&#xD;
      evaluated physiological assessment of coronary stenosis and its clinical effectiveness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Medical economy</measure>
    <time_frame>1 year after the procedure</time_frame>
    <description>To evaluate the healthcare cost-effectiveness in QALY（Quality Adjusted Life Year）converted by Japanese functional score ; Quality of Life(QOL) questionnaire (EQ-5D) and the cost postulated by CAG strategy with its iFR/FFR hybrid strategy.&#xD;
To collect the healthcare cost related MACCE at the timing of 6 and 12 months FU point. (Included emergency visit) To collect QOL questionnaire (EQ-5D) at the timing of just after the treatment and 12 months follow up point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physiological assessment</measure>
    <time_frame>baseline pocedure</time_frame>
    <description>Alteration in treatment protocol. Change in SYNTAX score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of major adverse cardiac and cerebrovascular events(MACCE)</measure>
    <time_frame>1year after the pocedure</time_frame>
    <description>MACCE include all-cause death, cerebrovascular accident(CVA), myocardial infarction(MI), and repeat revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlated analysis</measure>
    <time_frame>baseline pocedure</time_frame>
    <description>Area under receiver-operating characteristic curve(ROC) Classification agreement between iFR and FFR in this registry, Demonstrated using the area under the receiver-operating characteristic curve(FFR cut-off 0.8 or 0.75).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of variance</measure>
    <time_frame>beseline procedure</time_frame>
    <description>Treatment categorization disagreements of iFR and FFR are analyzed by multi-variable analysis processing to calculate Characteristic factors.</description>
  </secondary_outcome>
  <enrollment type="Actual">421</enrollment>
  <condition>Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient who is adaptable to CAG and/or coronary revascularization&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;=20 years old.&#xD;
&#xD;
          -  Patient who can understand informed consent of the clinical study and signed the&#xD;
             consent.&#xD;
&#xD;
          -  Patient who is adaptable to CAG and/or coronary revascularization&#xD;
&#xD;
          -  Patient who has evaluated stenotic lesion (stenosis&gt;50% in visual judgment) by CAG at&#xD;
             main epicardial vessel and its branch or who suspected to have it.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with known contraindications to Adenosine Triphosphate(ATP) and/or papaverine&#xD;
             hydrochloride&#xD;
&#xD;
          -  Target vessel diameter&lt;=2.0mm&#xD;
&#xD;
          -  Lesion with Chronic Total Occlusion(CTO) (registration allowed if other branch has&#xD;
             stenosis more than 50% in visual judgment)&#xD;
&#xD;
          -  Patient with temporary/permanent artificial pacemaker implantation, left bundle branch&#xD;
             block, second-degree and third-degree atrioventricular block.&#xD;
&#xD;
          -  Acute Myocardial Infarction(AMI) patient&#xD;
&#xD;
          -  Patient who is disqualified for FFR and coronary revascularization by the&#xD;
             investigator.&#xD;
&#xD;
          -  Lesion is disqualified for Percutaneous Coronary Intervention(PCI) by the&#xD;
             investigator.&#xD;
&#xD;
          -  Patient who has critical valvular disease of heart. (moderate or severe Aortic valve&#xD;
             stenosis(AS)/Aortic Regurgitation(AR)/Mitral Stenosis(MS)/Mitral Regurgitation(MR)）&#xD;
&#xD;
          -  Patient with a prior Coronary Artery Bypass Graft(CABG) on target vessel.&#xD;
&#xD;
          -  Patient with severe renal dysfunction. (serum creatinine&gt;=2.0mg/dl)&#xD;
&#xD;
          -  Patient on hemodialysis.&#xD;
&#xD;
          -  Body weight&gt;=200kg&#xD;
&#xD;
          -  Patient who needs ventricular assist device to ensure hemodynamic stability (heart&#xD;
             rate&lt;50/min, SBP&lt;90mmHg)&#xD;
&#xD;
          -  Patient who expects to live less than 2 years at the registration&#xD;
&#xD;
          -  Patient with contraindications to an antithrombotic therapy or an anticoagulant&#xD;
             therapy.&#xD;
&#xD;
          -  Patient who is poor compliance with drug treatment.&#xD;
&#xD;
          -  Patient who is allergic to contrast agent.&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction(LVEF)&gt;=30%&#xD;
&#xD;
          -  Patient who has the history of PCI with Drug-Eluting Stent(DES) in recent 3 months&#xD;
             before registration.&#xD;
&#xD;
          -  Patient who has the history of PCI with Bare Metal Stent(BMS) or Plain Old Balloon&#xD;
             Atherectomy(POBA) in recent 1 year before registration.&#xD;
&#xD;
          -  Patient who has possibility of pregnancy, under breast-feeding and positive pregnancy&#xD;
             test in 14days prior to the PCI.&#xD;
&#xD;
          -  Patients with inadequacy to join this clinical study.&#xD;
&#xD;
          -  Patient who has been enrolled any other clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masato Nakamura, M.D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>NPO Associations for Establishment of Evidence in Interventions</name>
      <address>
        <city>Minato</city>
        <state>Tokyo</state>
        <zip>105-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>October 28, 2013</study_first_submitted>
  <study_first_submitted_qc>December 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <last_update_submitted>January 26, 2017</last_update_submitted>
  <last_update_submitted_qc>January 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iFR</keyword>
  <keyword>FFR</keyword>
  <keyword>Medical Economy</keyword>
  <keyword>physiological assessment</keyword>
  <keyword>SYNTAX score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

